Oxybutynin Chloride
Pronouncation: (OX-ee-BYOO-tih-nin KLOR-ide)Class: Anticholinergic
Trade Names:
Ditropan
- Tablets 5 mg
- Syrup 5 mg/5 mL
Trade Names:
Ditropan XL
- Tablets, extended-release 5 mg
- Tablets, extended-release 10 mg
- Tablets, extended-release 15 mg
Trade Names:
Oxytrol
- Transdermal system 36 mg of oxybutynin delivering 3.9 mg of oxybutynin/day.
Gen-Oxybutynin (Canada)
Novo-Oxybutynin (Canada)
Nu-Oxybutynin (Canada)
PMS-Oxybutynin (Canada)
Pharmacology
Feedback for Oxybutynin Chloride
Compare with other drugs.
|
Increases bladder capacity, diminishes frequency of uninhibited contractions of detrusor muscle and delays initial desire to void.
Pharmacokinetics
Absorption
Extended-releaseFollowing oral administration of the oxybutynin extended-release (ER) tablet, plasma levels rise for 4 to 6 h; thereafter, steady levels are maintained for up to 24 h. Steady-state levels are achieved by day 3 of repeated ER dosing.
Transdermal systemFollowing application of the first 3.9 mg/day system, plasma levels increase for approximately 24 to 48 h; reaching C max of 3 to 4 ng/mL.
Distribution
Extended-releasePlasma concentrations of oxybutynin decline biexponentially following IV or oral administration. The Vd is 193 L after IV administration of 5 mg oxybutynin chloride.
Transdermal systemWidely distributed to body tissues. The Vd was estimated to be 193 L after IV administration of 5 mg oxybutynin chloride.
Metabolism
Extensively metabolized by the liver. Primarily by the CYP3A4 isozyme in the liver and gut wall. Transdermal administration bypasses the first-pass GI and hepatic metabolism.
Elimination
Less than 0.1% excreted unchanged in the urine.
Indications and Usage
Treatment of symptoms of bladder instability associated with voiding in patients with uninhibited and reflex neurogenic bladder (eg, urinary leakage, dysuria). Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency (ER tablet).
Contraindications
Untreated angle-closure glaucoma; untreated narrow anterior chamber angles; GI obstruction; paralytic ileus; intestinal atony of elderly or debilitated patients; toxic megacolon complicating ulcerative colitis; severe colitis; obstructive uropathy; myasthenia gravis; unstable CV status in acute hemorrhage.
Dosage and Administration
Adults Immediate-release tablet or syrupPO 5 mg 2 to 3 times daily (max, 5 mg 4 times daily).
ER tabletsPO 5 mg once daily adjusted in 5 mg increments at weekly intervals (max, 30 mg/day).
Children older than 5 yr of agePO 5 mg twice daily (max, 5 mg 3 times daily).
Transdermal systemAdults
Transdermal 3.9 mg/day applied twice/wk (every 3 or 4 days) to dry, intact skin on abdomen, hip, or buttock, selecting a new application site with each system and avoiding using the same site within 7 days.
General Advice
- Transdermal system
- Remove patch from foil pouch, remove plastic strips covering adhesive layer, and immediately apply to dry, intact skin on the abdomen, buttock, or hip.
- Rotate application sites to avoid reapplication to same site within 7 days.
- To discard used patch, fold used patch, place in foil pouch from new patch, and discard in trash.
Storage/Stability
Store tablets in tightly closed container at room temperature. Store patches in foil pouch at controlled room temperature (59° to 86°F). Protect from moisture and humidity. Do not store patches outside foil pouch.
Drug Interactions
Anticholinergic drugs (eg, amantadine)Increased risk of anticholinergic adverse reactions.
Beta-blockers (eg, atenolol)Atenolol plasma levels may be elevated, increasing the risk of adverse reactions.
DigoxinIncreased plasma levels of slow-dissolution oral tablets may be increased.
HaloperidolWorsening of schizophrenic symptoms; tardive dyskinesia; decreased serum haloperidol concentrations, reducing therapeutic effect.
PhenothiazinesDecreased therapeutic effects of phenothiazines; increased incidence of anticholinergic adverse reactions.
Laboratory Test Interactions
None well documented.
Adverse Reactions
Cardiovascular
Immediate-release tablets and syrupPalpitations; tachycardia; vasodilation.
ER tabletsTachycardia, palpitations, vasodilatation, hypertension, palpitation, vasodilation (2% to less than 5%).
CNS
Immediate-release tablets and syrupDizziness; drowsiness; hallucinations; insomnia; restlessness.
ER tabletsSomnolence (11.9%); headache (9.8%); dizziness (6.3%); drowsiness, hallucinations, restlessness, insomnia, nervousness, confusion (2% to less than 5%).
Transdermal systemFatigue; somnolence; headache (more than 1%).
Dermatologic
Immediate-release tablets and syrupDecreased sweating; rash.
ER tabletsRash, dry skin (2% to less than 5%).
Transdermal systemApplication-site pruritus, erythema, vesicles, rash and macules (2% or more).
EENT
Immediate-release tablets and syrupAmblyopia; cycloplegia; decreased lacrimation; mydriasis.
ER tabletsBlurred vision (7.7%); dry eyes (6.1%); decreased lacrimation; mydriasis; amblyopia; cycloplegia; rhinitis; sinusitis; dry nasal and sinus mucous membranes; pharyngitis.
Transdermal systemAbnormal vision (2% or more).
GI
Immediate-release tablets and syrupConstipation; decreased GI motility; dry mouth; nausea.
ER tabletsDry mouth (60.8%); constipation (13.1%); diarrhea (9.1%); nausea (8.9%); dyspepsia (6.8%); vomiting, decreased GI motility, flatulence, gastroesophageal reflux (2% to less than 5%).
Transdermal systemDry mouth, diarrhea, constipation (2% or more); abdominal pain, nausea, flatulence (more than 1%).
Genitourinary
Immediate-release tablets and syrupUrinary retention and hesitancy.
ER tabletsImpotence, UTI, increased postvoid residual volume, cystitis (2% to less than 5%).
Transdermal systemDysuria (2% or more).
Respiratory
ER tabletsUpper respiratory tract infection, cough, bronchitis (2% to less than 5%).
Miscellaneous
Immediate-release tablets and syrupAsthenia; impotence; suppression of lactation.
ER tabletsAsthenia, pain (6.8%); rhinitis (5.6%); UTI (5.1%); decreased sweating, suppression of lactation, abdominal pain, accidental injury, back pain, flu-like syndrome, arthritis (2% to less than 5%).
Transdermal systemFlushing, back pain, application-site burning (more than 1%).
Precautions
Pregnancy
Category B .
Lactation
Undetermined.
Children
Safety and efficacy in children younger than 5 yr of age not established.
Special Risk Patients
Use with caution in the elderly and in patients with renal or hepatic function impairment or autonomic neuropathy.
Anticholinergic effects
Use cautiously with phenothiazines or other drugs with anticholinergic properties because adverse reactions will be additive.
Cardiac and other effects
May aggravate symptoms of hyperthyroidism, coronary heart disease, CHF, cardiac arrhythmias, tachycardia, hypertension, hiatal hernia, and prostatic hypertrophy.
Diarrhea
Diarrhea may be an early symptom of intestinal obstruction in which oxybutynin is contraindicated.
GI disorders
Administration to patients with ulcerative colitis may suppress GI motility and produce paralytic ileus, precipitating or aggravating toxic megacolon.
Heat prostration
Heat prostration may occur when exposed to high environmental temperature.
Urinary retention
Because risk may be increased, use with caution.
Overdosage
Symptoms
CNS excitation, flushing, fever, tachycardia, nausea, respiratory depression, coma.
Patient Information
- Instruct patient to take sips of water frequently, suck on ice chips or sugarless hard candy, or chew sugarless gum if dry mouth occurs.
- Teach patient to use bladder massage to empty bladder.
- Advise patient to use caution in hot weather to reduce risk of heat stroke.
- Advise patient that drug may cause drowsiness or dizziness, and to use caution while driving or performing other tasks requiring mental alertness.
- Advise patient to take oxybutynin ER tablet whole with liquids and not to chew, divide, or crush.
- Inform patient not to be concerned if noticing a tablet in the stool; the tablet shell is eliminated from the body but the drug is released from the tablet at a controlled rate.
- Transdermal system
- Advise patient to review the patient information leaflet that comes with each prescription before using the first time and with each refill.
- Ensure that patient understands how to store, apply, and discard patches.
- Advise patient that new patch is applied twice/wk (eg, every 3 to 4 days) and to rotate application sites to avoid reapplication to the same site within 7 days.
- Advise patient that if patch comes off before scheduled replacement, to discard and apply new patch to new application site and establish new reapplication schedule.
- Advise patient to notify health care provider if application-site reactions occur and are bothersome or occur with each application.
| Link to this page | ![]() |
Printable Version | ![]() |
Email Page | ![]() |
Add to my drug list |
More Oxybutynin Chloride resources:
Ditropan XL Extended-Release Tablets
Ditropan - Includes detailed dosage instructions.
Oxybutynin Chloride Drug Interactions
Overactive Bladder, Urinary Incontinence













